Clay Siegall is the co-founder of Seattle Genetics since 1998. He started the company with the idea of improving people’s lives by using targeted therapies to kill cancer cells. Clay Siegall is a trained scientist who built Seattle Genetics to develop drug practices, perform extensive research and improve your quality of life. Under his leadership he has helped Seattle Genetics create ADCETRIS, their first FDA approved product for the treatment of cancer. ADCETRIS is a global brand that is currently approved in over 70 countries. They have also entered into multiple licenses for their ADCETRIS technology, including AbbVie, Pfizer, Astellas, GlaxoSmithKline and Genentech (Roche). Using Seattle Genetics’ technology, there are more than 20 ADC’s currently in clinical development. Clay Siegall is also responsible for the capital-raising activities for Seattle Genetics. He has helped secure over $1 billion through private and public financing. Clay has worked for the National Institutes of Health, National Cancer Institute and the Bristol-Myers Squibb Pharmaceutical Research Institute. He has been honored with the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences award and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year award. He has written over 70 publications and graduated from George Washington University with a Ph.D. in Genetics. Siegall also have a B.S. in Zoology from the University of Maryland.
Seattle Genetics is one of the largest oncology biotechnology company in the Pacific Northwest. Their innovative ADC technology combines potent cell eliminating agents, linker systems and monoclonal antibodies to kill cancer. Seattle Genetics has proven to improve the outcomes of their patients living with cancer. They are becoming the leader in transforming cancer therapy through its advanced research into ADC technology.